Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma
Cancer Network,
The expert panel The assessment of updated clinical trial data, optimal dosing strategies, and integration of bispecific…
Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
Overview of attention for article published in Blood, November 2023
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
High Attention Score compared to outputs of the same age and source (87th percentile)
Readers on
- mendeley
- 24 Mendeley
